Skip to main content

Table 1 Clinical characteristics for responders and non-responders for ibuprofen treatment for PDA

From: Baseline cardiac output and its alterations during ibuprofen treatment for patent ductus arteriosus in preterm infants

Demographics Responders Non-Responders p valuea
(n = 9) (n = 9)
Gestational age (weeks) 27.7 (27.1–29.9) 27.4 (26.1–27.9) 0.161
Weight (g) 1135 (913–1318) 1015 (830–1083) 0.222
Apgar at 1 min 7 (5–8) 6 (3–7) 0.077
Apgar at 5 min 9 (7–9) 9 (8–9) 0.931
Male 6 (67%) 2 (22%) 0.153
Cesarean section 6 (67%) 7 (78%) 1.000
Small for gestational age 2 (22%) 1 (11%) 1.000
Echocardiography prior to ibuprofen treatment
 PDA diameter (mm) 2.05 (1.78–2.46) 2.20 (1.70–3.23) 0.666
 PDA diameter to weight (mm/kg) 2.04 (1.40–2.54) 2.26 (1.56–3.57) 0.340
 PDA maximum flow velocity (m/s) 2.21 (1.59–2.60) 1.82 (1.30–2.52) 0.613
 LA/Ao ratio 1.47 (1.27–1.76) 1.50 (1.44–1.87) 0.370
 Fractional shortening (%) 41.0 (36.0–44.5) 39.0 (34.2–43.8) 0.661
Condition prior to ibuprofen treatment
 Post-natal age at dose #1 (day) 3.0 (3.0–4.0) 4.0 (3.0–6.5) 0.222
 Oral ibuprofen 8 (89%) 7 (78%) 1.000
 Respiratory support    0.183
 Non-invasive ventilation 5 (56%) 2 (22%)  
 Conventional ventilation 4 (44%) 5 (56%)  
 High frequency ventilation 0 (0%) 2 (22%)  
  1. PDA patent ductus arteriosus, LA/Ao left atrium to aortic root diameter
  2. Data are median (interquartile range) or n (%)
  3. aA p value was tested by Mann-Whitney U test for continuous variables and Chi-square test or Fisher’s exact test for categorical data